Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st:
CNA Financial Corporation (CNA - Free Report) : This provider of commercial property and casualty insurance products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.
CNA Financial’s shares gained 10% over the last one month above the S&P 500’s increase of 1.6%. The company possesses a Momentum Score of A.
Electromed, Inc. (ELMD - Free Report) : This manufacturer of airway clearance therapy and related products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Electromed’s shares gained 21.1% over the last one month. The company possesses a Momentum Score of A.
Pacira BioSciences, Inc. (PCRX - Free Report) : This provider ofnon-opioid pain management and regenerative health solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.
Pacira BioSciences’ shares gained 12.4% over the last one month. The company possesses a Momentum Score of A.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) : This biopharmaceutical company carries a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
Regeneron Pharmaceuticals’ shares gained 9.7% over the last one month. The company possesses a Momentum Score of A.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 21st:
CNA Financial Corporation (CNA - Free Report) : This provider of commercial property and casualty insurance products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.7% over the last 60 days.
CNA Financial’s shares gained 10% over the last one month above the S&P 500’s increase of 1.6%. The company possesses a Momentum Score of A.
Electromed, Inc. (ELMD - Free Report) : This manufacturer of airway clearance therapy and related products has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 16.7% over the last 60 days.
Electromed’s shares gained 21.1% over the last one month. The company possesses a Momentum Score of A.
Pacira BioSciences, Inc. (PCRX - Free Report) : This provider ofnon-opioid pain management and regenerative health solutions has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.7% over the last 60 days.
Pacira BioSciences’ shares gained 12.4% over the last one month. The company possesses a Momentum Score of A.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report) : This biopharmaceutical company carries a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.8% over the last 60 days.
Regeneron Pharmaceuticals’ shares gained 9.7% over the last one month. The company possesses a Momentum Score of A.
See the full list of top ranked stocks here
Learn more about the Momentum score and how it is calculated here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on REGN - FREE
Get the latest research report on CNA - FREE
Get the latest research report on ELMD - FREE
Get the latest research report on PCRX - FREE